Despite the billions of dollars invested in research over the last several decades, the underlying causes of Alzheimer’s have remained stubbornly murky. Early theories focused almost exclusively on the plaques themselves, but clinical trials targeting those plaques have often yielded disappointing results, failing to stop the cognitive slide even when the plaques were successfully cleared. This has led scientists to look for earlier triggers in the disease’s "cascade."
The UVA study adds to a growing body of evidence that the immune system—and specifically the brain’s resident immune cells, known as microglia—is the missing piece of the puzzle. When STING is activated, it directs these microglia to adopt a pro-inflammatory state. In their attempt to respond to the perceived threat of damaged DNA, these cells become hyperactive, damaging the very synapses and neurons they are supposed to support.
By focusing on STING, the UVA researchers are looking upstream of the plaques and tangles. They found that by blocking this molecule’s activity in laboratory mice, they could effectively "quiet" the immune response. This intervention not only prevented the formation of amyloid plaques but also altered the activity of microglia in a way that protected the brain’s architecture and preserved memory function.
"We found that removing STING dampened microglial activation around amyloid plaques, protected nearby neurons from damage and improved memory function in Alzheimer’s model mice," explained Jessica Thanos, a researcher in UVA’s Department of Neuroscience and the Center for Brain Immunology and Glia (BIG Center). "Together, these findings suggest that STING drives detrimental immune responses in the brain that exacerbate neuronal damage and contribute to cognitive decline in Alzheimer’s disease."
Promising Treatment Target
One of the most significant aspects of this discovery is that STING appears to be a "dual-threat" target. In the complex landscape of Alzheimer’s pathology, there are two primary villains: amyloid-beta plaques and tau tangles. Most experimental drugs target one or the other, often with limited success because the two processes are deeply intertwined.
The UVA Health researchers found that STING is uniquely positioned because it appears to influence both. Blocking the molecule slowed the buildup of plaques while simultaneously hindering the development of tau tangles. This robust involvement makes STING a much more attractive target than other molecules that may only be relevant during very specific, narrow windows of the disease’s progression.
Furthermore, the implications of this discovery extend far beyond Alzheimer’s. Because STING responds to the fundamental biological process of DNA damage and inflammation, it is likely a key contributor to a spectrum of neurodegenerative conditions. The researchers believe that therapies targeting STING could eventually be used to treat Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and various forms of dementia.
"We are only beginning to understand the complex role of innate immune activation in the brain, and this is especially true in both normal and pathological aging," Thanos said. "If we can pinpoint which cells and signals sustain that activation, we will be in a much better position to intervene effectively in disease."
